Program
Chickenpox Vaccine
Also written as “Varicella Vaccine”, “Investigational live attenuated varicella vaccine” and “Zoster Vaccine, Live”.
Its studies are mostly in Chickenpox · Herpes Zoster · Meningococcal Infections · Measles · Streptococcal Infections, led by 6 companies.
Drug pageChickenpox Vaccine: every studyMany companies study it; this page follows only the 43 they lead. All 76 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 210 open or running | phase 4since Feb 7, 2007 | Apr 22, 2005 | none ahead |
| Sinovac Biotechits history only | 124 open or running | phase 4since Oct 14, 2021 | Nov 14, 2016 | Dec 2028phase 4 · NCT06484686 |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Sinopharmits history only | 22 open or running | phase 3since Dec 20, 2022 | Dec 20, 2022 | none ahead |
| Changchun Changsheng Life Science and Technologyits history only | 10 open or running | phase 4since Oct 24, 2013 | Oct 24, 2013 | none ahead |
| GC Biopharmaits history only | 10 open or running | phase 3since Nov 28, 2017 | Nov 28, 2017 | none ahead |
Also a collaborator on its studies: Beijing Institute of Biological Products.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Apr 22, 2005.
- Sep 21, 2007Phase 3 study in Herpes ZosterNCT00534248 · 22,439 enrolled
- Oct 17, 2007Phase 2 study in Herpes ZosterNCT00546819 · 309 enrolled
- Oct 29, 2007Phase 4 study in Herpes ZosterNCT00550745 · 11,999 enrolled
- Nov 19, 2007Phase 3 study in Prevention of : Herpes-ZosterNCT00561080 · 759 enrolled
- May 16, 2008Phase 4 study in Herpes ZosterNCT00681031 · 96 enrolled
- Jan 9, 2009Phase 3 study in ChickenpoxNCT00822237 · 598 enrolled
- Nov 19, 2010Phase 3 study in Herpes ZosterNCT01245751 · 600 enrolled
- Jun 28, 2011Phase 1 study in Herpes ZosterNCT01385566 · 223 enrolled
- Jul 7, 2011Phase 3 study in Herpes ZosterNCT01391546 · 354 enrolled
- Jan 4, 2012Phase 3 study in Herpes ZosterNCT01505647 · 498 enrolled
- Feb 2, 2012Phase 3 study in Herpes ZosterNCT01527370 · 250 enrolled
- Feb 17, 2012Phase 4 study in Herpes ZosterNCT01556451 · 180 enrolled
- Aug 7, 2015Phase 3 study in Herpes ZosterNCT02519855 · 882 enrolled
- Feb 14, 2019Phase 3 study in ChickenpoxNCT03843632 · 150 enrolled · Russian Federation
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 21 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03843632Chickenpox · Russian Federation | 3 | Completed | Jun 19, 2020 | 150 |
| NCT02519855Herpes Zoster | 3 | Completed | Jan 26, 2016 | 882 |
| NCT01556451Herpes Zoster | 4 | Completed | Oct 2012 | 180 |
| NCT01527370Herpes Zoster | 3 | Completed | Apr 9, 2013 | 250 |
| NCT01505647Herpes Zoster | 3 | Completed | Jul 2012 | 498 |
| NCT01391546Herpes Zoster | 3 | Completed | Oct 15, 2012 | 354 |
| NCT01385566Herpes Zoster | 1 | Completed | May 2013 | 223 |
| NCT01245751Herpes Zoster | 3 | Completed | Jul 2012 | 600 |
| NCT00822237Chickenpox | 3 | Completed | Oct 2009 | 598 |
| NCT00681031Herpes Zoster | 4 | Completed | Jun 25, 2008 | 96 |
| NCT00561080Prevention of : Herpes-Zoster | 3 | Completed | Jun 3, 2009 | 759 |
| NCT00550745Herpes Zoster | 4 | Completed | Jan 2009 | 11,999 |
| NCT00546819Herpes Zoster | 2 | Completed | Aug 2010 | 309 |
| NCT00534248Herpes Zoster | 3 | Completed | Jan 2010 | 22,439 |
| NCT00496327Chickenpox | 3 | Completed | Oct 6, 2005 | 100 |
| NCT00444860Varicella Virus Infection | 3 | Completed | May 2007 | 150 |
| NCT00432731Chickenpox · France, Italy | 4 | Completed | Sep 2005 | 500 |
| NCT00432523Measles · France, Germany | 3 | Completed | Sep 5, 2005 | 752 |
| NCT00322231Herpes Zoster | 3 | Completed | Jul 2007 | 101 |
| NCT00231816Herpes Zoster | 3 | Completed | Mar 2006 | 763 |
| NCT00109122Herpes Zoster | 2 | Completed | Feb 2003 | 180 |
How it is read
Names in the registry
- “Varicella Vaccine”, 4 entries
- “Investigational live attenuated varicella vaccine”, 4 entries
- “Zoster Vaccine, Live”, 3 entries
- “Varicella Virus Vaccine Live”, 2 entries
- “Live Attenuated Varicella Vaccine”, 2 entries
Conditions, from the studies’ own filings
- Chickenpox, 24 studies
- Herpes Zoster, 15 studies
- Meningococcal Infections, 1 study
- Measles, 1 study
- Streptococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.